Treatment
[The Current Therapy of Asbestos-Associated Malignant Pleural Mesothelioma – An Expert Consensus Paper]
Pneumologie 2021 May 4 [Link] C Aigner, T Brüning, W E E Eberhardt, M Härter, H-P Kaelberlah, M Metzenmacher, R Shah, C Taube, M Thomas Abstract Asbestos-related mesotheliomas belong to the group of the most frequent occupational diseases in Germany, reaching about 1,000 new cases per year. The disease has a dismal prognosis because most…
Read MoreSarcomatoid Mesothelioma: A Clinicopathological and Immunohistochemical Study of 64 Cases
International Journal of Surgical Pathology 2021 May 3 [Link] Diana M Oramas, Michael Zaleski, Cesar A Moran Abstract Sixty-four cases of sarcomatoid pleural mesothelioma represent the basis of this study. The patients are 51 men and 13 women between the ages of 42 and 79 years, who presented with symptoms of chest pain, cough, and…
Read MoreComplete laparoscopic pelvic peritonectomy plus hyperthermic intraperitoneal chemotherapy
Techniques in Coloproctology 2020 October [Link] A Arjona-Sánchez, D Cortés-Guiral, M Duran-Martínez, P Villarejo-Campos, J M Sánchez-Hidalgo, A Casado-Adam, L Rodriguez-Ortiz, A Romero-Ruiz, B Rufian-Andujar, E Espinosa-Redondo, F Valenzuela-Molina, S Rufián-Peña, J Briceño-Delgado Abstract Background: The aim of our study was to present the technique for, and early results of complete laparoscopic pelvic peritonectomy (LPP)…
Read MoreUnusually favorable outcome of 6 consecutive patients with diffuse malignant peritoneal mesothelioma treated with repeated doses of intraperitoneal paclitaxel. A case series
Surgical Oncology 2020 June [Link] Paul H Sugarbaker, O Anthony Stuart Abstract Background: Diffuse malignant peritoneal mesothelioma (DMPM) is a disease in transition. Two decades ago this cancer had a median survival of 1 year. Recent reports in selected patients show a 5-year survival of 70% and median survival not reached at 10 years. Methods:…
Read MoreThree Decades of Malignant Pleural Mesothelioma: An Academic Center Experience
Clinical Lung Cancer 2021 March 27 [Link] Abdullah Nasser, Andrew Baird, Mathieu D Saint-Pierre, Kayvan Amjadi, Scott Laurie, Paul Wheatley-Price Abstract Background: Malignant pleural mesothelioma (MPM) remains a challenging disease to manage. In the past few decades, extrapleural pneumonectomy (EPP), pemetrexed-based chemotherapy, and indwelling pleural catheters were introduced to MPM care with variable levels of…
Read More[BRIC-59 study: first results and considerations on the pathway on the access to health care for malignant pleural mesotheliomas]
Epidemiologia e Prevenzione Jan-Apr 2021 [Link] Elisabetta Chellini, Martina Donzellini, Sara Ricciardi, Lucia Kundisova, Lucia Giovannetti, Francesca Battisti, Martina Giusti, Barbara Dallarti, Carolina Mensi Abstract Objectives: to define the most frequent health pathways of cases affected by malignant pleural mesothelioma according to those suggested and evaluated by the most recent specific guidelines. Design: epidemiological descriptive…
Read MoreSulforaphane inhibits PRMT5 and MEP50 function to suppress the mesothelioma cancer cell phenotype
Molecular Carcinogenesis 2021 April 19 [Link] Geraldine Ezeka, Gautam Adhikary, Sivaveera Kandasamy, Joseph S Friedberg, Richard L Eckert Abstract Mesothelioma is a highly aggressive cancer of the mesothelial lining that is caused by exposure to asbestos. Surgical resection followed by chemotherapy is the current treatment strategy, but this is marginally successful and leads to drug-resistant…
Read MoreTertiary lymphoid structures in epithelioid malignant peritoneal mesothelioma are associated with neoadjuvant chemotherapy, but not with prognosis
Virchows Archiv 2021 April 14 [Link] Nazim Benzerdjeb, Peggy Dartigues, Vahan Kepenekian, Séverine Valmary-Degano, Eliane Mery, Gerlinde Avérous, Anne Chevallier, Marie-Hélène Laverriere, Irène Villa, Olivier Harou, Françoise Galateau Sallé, Laurent Villeneuve, Olivier Glehen, Sylvie Isaac 8, Juliette Hommell-Fontaine, Frédéric Bibeau Abstract Epithelioid mesothelioma is the most prevalent subtype of diffuse malignant peritoneal mesothelioma. The relationship…
Read MoreP14/ARF-Positive Malignant Pleural Mesothelioma: A Phenotype With Distinct Immune Microenvironment
Frontiers in Oncology 2021 March 22 [Link] Federica Pezzuto, Francesca Lunardi, Luca Vedovelli, Francesco Fortarezza, Loredana Urso, Federica Grosso, Giovanni Luca Ceresoli, Izidor Kern, Gregor Vlacic, Eleonora Faccioli, Marco Schiavon, Dario Gregori, Federico Rea, Giulia Pasello, Fiorella Calabrese Abstract Introduction: The CDKN2A gene plays a central role in the pathogenesis of malignant pleural mesothelioma (MPM).…
Read MorePremature phase II study of amrubicin as palliative chemotherapy for previously treated malignant pleural mesothelioma
Thoracic Cancer 2021 April 8 [Link] Kageaki Watanabe, Yusuke Okuma, Shoko Kawai, Makoto Nagamata, Yukio Hosomi Abstract Background: Treatment options for malignant pleural mesothelioma (MPM) are limited. Anthracyclines are considered key drugs for treating MPM. However, their use is limited by severe cardiac toxicities. Amrubicin (AMR) is a next-generation anthracycline that is commonly used to…
Read More